Naslov
Treatment of multiple sclerosis

Autori
Brinar, Vesna ; Petelin, Željka

Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), ostalo

Izvornik
South East European Society for Neurology and Psychiatry 43rd International Neuropsychiatric Pula Symposium Proceedings / Barac, Boško ; Huber, Gerd ; Lechner, Helmut ; Muačević, Vasko - Zagreb, 2003, 142-144

Skup
International Neuropsychiatric Pula Symposium (43 ; 2003)

Mjesto i datum
Pula, Hrvatska, 18.06.2003. - 21.06.2003

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
multiple sclerosis; treatment; clinical trials

Sažetak
This paper presents recommendations for the treatment of patients with multiple sclerosis (MS). The value of individual therapeutic agents in the treatment of acute phase, as well as the possibility of prevention of new relapses and progress of the disease has been assessed. On the basis of class I trials interferon beta (IFNβ ) has been demonstrated to reduce the attack rate (measured clinically and by magnetic resonance imaging - MRI) in patients with MS or with clinically isolated syndrome who are at high risk for developing MS. Treatment of MS with IFNβ produces a beneficial effect on disease severity (measured clinically or by MRI) and probably slows sustained disability progression. Treatment with glatiramer acetate also produces a beneficial effect on disease severity (results based on clinical and MRI findings) and possibly also slows sustained disability progression in patients with relapsing-remitting multiple sclerosis (RRMS). Many studies have established the partial effect of different immunosupressive therapies. Clinical trials of mitoxantron hydrochloride have shown that this synthetic anaplastic agent decreases clinical symptoms and proofs of disease activity visible by MRI in SPMS patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA